Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALATHEA benralizumab in eosinophilic COPD
NL-OMON41749Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annual COPD exacerbation rate. Started Aug 2014; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON41749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41749.